Literature DB >> 26520143

Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC).

Ting Shuang1, Min Wang2, Yingying Zhou1, Cong Shi1.   

Abstract

Ovarian cancer is the most lethal malignancy in female patients, and chemoresistance is the major contribution to low over survival rate. We aim to investigate the correction between Sirt1 expression and chemoresistance in serous epithelial ovarian cancer (EOC) and prognosis significance of Sirt1. Immunochemistry was used to determine the location pattern and expression of Sirt1 in a total of 63 serous EOC patients (28 cases of chemoresistance patients and 35 chemosensitive).The relationship between Sirt1 expression and clinicopathological features of serous EOC was analyzed. Univariate analysis and multifactor logistic regression analysis were applied to investigate risk factor for chemoresistance. Cox proportional hazards regression model and Kaplan-Meier survival analysis were applied to determine the prognosis factor and survival time. Immunohistochemistry proved that over-expression of nuclear Sirt1 was related to chemoresistance (P = 0.039). Multivariate logistic regression analysis proved that the nuclear expression of Sirt1 (P = 0.018) and the lymph node metastasis (P = 0.037) was independent risk factors for chemoresistance in serous epithelial ovarian cancer. Multivariate Cox regression result indicated that expression of Sirt1 (P = 0.026, RR 2.434, 95 % CI 1.109-5.339) and stage (P = 0.005, RR 2.366, 95 % CI 1.288-4.345) was independent prognostic factors. Kaplan-Meier analysis showed that the survival rate is significantly decreased in the Sirt1 highly expressed group. Western blot result showed that the protein level of Sirt1 was significantly higher in chemoresistant group compared with in sensitive group. In conclusion, our results proved that over-expression of Sirt1 could play an important role in chemoresistance of serous EOC and could be a prognosis indicator for the patient's survival outcome.

Entities:  

Keywords:  Chemoresistance; Ovarian cancer; Prognosis; Sirt1; Survival analysis

Mesh:

Substances:

Year:  2015        PMID: 26520143     DOI: 10.1007/s12032-015-0706-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

Review 1.  Sirtuins as regulators of metabolism and healthspan.

Authors:  Riekelt H Houtkooper; Eija Pirinen; Johan Auwerx
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-07       Impact factor: 94.444

2.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.

Authors:  S Imai; C M Armstrong; M Kaeberlein; L Guarente
Journal:  Nature       Date:  2000-02-17       Impact factor: 49.962

3.  Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.

Authors:  Sang Jae Noh; Hyun Ah Baek; Ho Sung Park; Kyu Yun Jang; Woo Sung Moon; Myoung Jae Kang; Dong Geun Lee; Min Ho Kim; Ju Hyung Lee; Myoung Ja Chung
Journal:  Pathol Res Pract       Date:  2013-04-15       Impact factor: 3.250

4.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 5.  Sirtuins: critical regulators at the crossroads between cancer and aging.

Authors:  L R Saunders; E Verdin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

6.  SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration.

Authors:  Lin Han; Xiao-Hua Liang; Li-Xin Chen; Shi-Min Bao; Zhi-Qiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

Review 7.  Roles of SIRT1 in leukemogenesis.

Authors:  WenYong Chen; Ravi Bhatia
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

8.  SIRT1 is significantly elevated in mouse and human prostate cancer.

Authors:  Derek M Huffman; William E Grizzle; Marcas M Bamman; Jeong-su Kim; Isam A Eltoum; Ada Elgavish; Tim R Nagy
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

9.  SIRT1 expression is associated with poor prognosis of lung adenocarcinoma.

Authors:  Chong Li; Lingling Wang; Liang Zheng; Xianghong Zhan; Bin Xu; Jingting Jiang; Changping Wu
Journal:  Onco Targets Ther       Date:  2015-04-30       Impact factor: 4.147

Review 10.  Primary ovarian cancer chemotherapy: current standards of care.

Authors:  W P McGuire; M Markman
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

View more
  23 in total

1.  SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.

Authors:  Michela Muscolini; Luciano Castiello; Enrico Palermo; Alessandra Zevini; Matteo Ferrari; David Olagnier; John Hiscott
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

2.  MicroRNA-29c restores cisplatin sensitivity in liver cancer through direct inhibition of sirtuin 1 expression.

Authors:  Wei Zhang; Peng Luo
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

3.  miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1.

Authors:  Hanchun Chen; Qiong Lu; Xifeng Fei; Likui Shen; Dongyi Jiang; Dongwei Dai
Journal:  Tumour Biol       Date:  2015-12-10

4.  SIRT1 and gynecological malignancies (Review).

Authors:  Jiayu Chen; Houzao Chen; Lingya Pan
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

5.  miR-22 inhibits mouse ovarian granulosa cell apoptosis by targeting SIRT1.

Authors:  Fang Xiong; Lingqing Hu; Yun Zhang; Xiao Xiao; Juxia Xiao
Journal:  Biol Open       Date:  2016-02-24       Impact factor: 2.422

6.  Knockdown of SIRT1 Suppresses Bladder Cancer Cell Proliferation and Migration and Induces Cell Cycle Arrest and Antioxidant Response through FOXO3a-Mediated Pathways.

Authors:  Qingxuan Hu; Gang Wang; Jianping Peng; Guofeng Qian; Wei Jiang; Conghua Xie; Yu Xiao; Xinghuan Wang
Journal:  Biomed Res Int       Date:  2017-09-25       Impact factor: 3.411

7.  Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality.

Authors:  Giulia Pinton; Stefan Nilsson; Laura Moro
Journal:  Oncogenesis       Date:  2018-02-09       Impact factor: 7.485

8.  Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression.

Authors:  Jie Qin; Yan Liu; Yongkui Lu; Meiling Liu; Manli Li; Juan Li; Lijuan Wu
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

Review 9.  Trending topics of SIRT1 in tumorigenicity.

Authors:  Liz M Garcia-Peterson; Xiaoling Li
Journal:  Biochim Biophys Acta Gen Subj       Date:  2021-06-18       Impact factor: 4.117

10.  MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1.

Authors:  Hui Liu; Xin-Hua Cheng
Journal:  Oncotarget       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.